

24 September 2024

Botanix presentation at leading investor conferences and roadshow

Key highlights

- Botanix Pharmaceuticals begins a non-deal investor roadshow today and will participate in two leading investor conferences this week
- Botanix CEO Dr Howie McKibbon will be a featured presenter at ASX Small and Mid-Cap Conference and the E&P Small Cap Healthcare Conference on Wednesday and Thursday, respectively
- Both conferences bring together institutional and sophisticated investors from around Australia and internationally to hear from leading companies on the ASX and in the life sciences sector
- Botanix will also be meeting with many of the leading institutional investors in the healthcare space in one-on-one meetings to provide an update on progress towards commercialisation of *Sofdra*[™], as launch readiness activities accelerate

Philadelphia and Phoenix US, 24 September 2024: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”), is pleased to announce the Company’s participation in two important conferences this week alongside an investor roadshow. Botanix Chief Executive Officer Howie McKibbon will be a featured presenter at ASX Small and Mid-Cap Conference on Wednesday, 25 September, followed by the E&P Small Cap Healthcare Conference on Thursday, 26 September. Both conferences bring together institutional and sophisticated investors from around Australia and internationally to hear from leading companies on the ASX and the life sciences sector, respectively.

Botanix will also be conducting one-on-one meetings with many of the leading Australian healthcare investors in a non-deal road show to provide an update on progress towards commercialisation of *Sofdra*[™], as launch readiness activities accelerate.

A copy of the presentation being used by the Company this week following its recent Commercial Day Update on 16 September is attached to this press release.

This ASX announcement is authorised for release by the Board.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra*[™] for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to

treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

HACK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company's ability to obtain marketing approvals for its product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of *Sofdra*[™] and the market for *Sofdra*. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.



Botanix Pharmaceuticals

September 2024

 **Sofdra**
(sofpironium) topical gel, 12.45%

September 2024

WWW.BOTANIXPHARMA.COM

Botanix overview

DERMATOLOGY FOCUS	WORLD CLASS TEAM	NEW PRODUCT “SOFDRA”	NOW FDA APPROVED	WELL CAPITALISED
New treatments for underserved common skin diseases, with a first focus on excessive sweating (“primary axillary hyperhidrosis”)	US-based team that have been responsible for successful development and commercial launches of more than 30 drugs	<i>Sofdra</i> [™] is the first and only new chemical entity for primary axillary hyperhidrosis (5% product already approved in Japan with solid sales)	Approved by FDA for the topical treatment of primary axillary hyperhidrosis in adults and children 9 years of age and older	~A\$79 million at end of the financial year to fund commercial launch of <i>Sofdra</i> and expansion of platform

WWW.BOTANIXPHARMA.COM

Final preparations for Patient Experience Program with *Sofdra* complete


Corporate Overview

ASX: BOT TRADING INFORMATION

Share price	A\$0.39
6-month low / high	A\$0.19/0.44
Shares outstanding	1,814,037,788
Market Capitalization	A\$707m
Cash	A\$79m
Debt	Nil

SUBSTANTIAL SHAREHOLDERS


Shareholder	%
Antares Capital	10.2%
Board and Management	6.0%
Top 20	34.6%



Hyperhidrosis

A medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature

- ❖ Results from overstimulation of the nervous system (a physiological not psychological condition)¹
- ❖ 90% of axillary (underarm) patients also have it in a second region¹
- ❖ The most common age of onset for axillary hyperhidrosis patients is 12–17²
- ❖ Market for treatments is ~\$US1.6B per annum—projected to grow to \$US2.8B by 2030²



FREQUENTLY
CHANGE
CLOTHES



FRESHEN UP
BY WIPING OR
BATHING




PLACE NAPKINS OR
PADS UNDER THEIR
ARMS OR THEIR
POCKETS



HIDE UNDER
DARK-COLOURED,
BULKY CLOTHES

Sofdra mechanism of action

Binds selectively to the M3-AC receptors in the sweat gland, blocks acetylcholine to inhibit sweat and is rapidly metabolized




M3 AC Receptors = Muscarinic Acetylcholine Receptors which regulate the function of sweat glands

Sofpironium Metabolite = Sofpironium is converted into a less active form to help minimize side effects

Both Phase 3 clinical study co-primary endpoints were highly statistically significant

POOLED DATA (CARDIGAN I AND II)


≥2-point improvement in HDSM-Ax-7 from baseline to end of treatment¹



HDSM-Ax-7 scale measures patient reported severity of axillary (underarm) hyperhidrosis

POOLED DATA (CARDIGAN I AND II)


GSP change from baseline to end of treatment¹



GSP (Gravimetric Sweat Production) is an objective measurement of underarm sweat production (mg/ 5 min)


Sofdra has a significant opportunity as a new treatment option for hyperhidrosis patients

No new chemical entities have ever been approved for hyperhidrosis




Due to its significant psychological impact, 54% of respondents suffering from hyperhidrosis say that they would pay anything for a treatment to stop their excessive sweating¹

Targeting the patients and the dermatologists in the office and separately accessing the untreated patients



Botanix sales force deployment

Three Regions: Northeast, Central & West (9 per Region)



Engaging a highly qualified segment of our priority targets

Sofdra™ Patient Experience Program (PEP)



- ❖ Highly qualified patients selected from the IHhS database will utilize the platform to gain early access to *Sofdra*
- ❖ At points in the PEP process, participants will be asked to take surveys to give feedback on the telemedicine and product access experience
- ❖ Patient feedback from survey responses will be used to improve the platform for hyperhidrosis patients
- ❖ The PEP will provide first revenues, data on conversion rates for prospective patient leads and prepare for full commercial launch in Q1 CY2025

Accessing *Sofdra*TM and providing feedback

Email invite by IHhS



Click thru to telehealth




Diagnose and ship



Survey and adjust

The image displays three overlapping mobile app screens from the Sofdra patient experience program. The top screen, titled "Welcome to the SofdraTM Patient Experience Program", includes a welcome message and a survey about insurance coverage. It features three blue buttons: "I Have Commercial Insurance", "I Have Government Insurance", and "I Don't Have Insurance". The middle screen shows a "Please select any of the following that apply to you" section with four options: "Others in my family have excessive sweating", "My excessive sweating started before age 25", "My excessive sweating has occurred for at least 6 months without apparent cause", and "I have at least one episode per week". The bottom screen shows a question about "Sweating on underarm pits same side" with a blue button for "Yes". Each screen has a Sofdra logo at the top and a navigation bar at the bottom.

Distinct health and behavioral signals identify patients in the most need, exactly when they need it



Hone in on actual patients while sharing sweat stories with AI social sentiment targeting

There were 396,464+ highly qualified hyperhidrosis patients talking about their symptoms and personal journeys last month¹

1 SOCIAL POSTS/HASHTAGS



HASHTAG EXAMPLES:


- #hyperhidrosis
- #sweatypits
- #sweatfree
- #excessivesweating
- #sweatproblems
- #sweatissues



2 IMAGES/VIDEOS




3 AUDIO RECOGNITION



1. Klick Health social listening survey May 2024 – data on file

Telemedicine platforms are now a mainstream tool for many companies in a wide range of indications



Pfizer: Nurtec ODT brand.com page, with link to the telehealth platform


Migraine	
	 
Psychiatry	Birth Control
	
Diabetes	Respiratory
 	
Obesity	Gastroenterology
 	

WWW.BOTANIXPHARMA.COM

Patient Path - UpScript's fully integrated model allows patients direct access from anywhere 24/7



Sofdra™ Patient Path



★ Information gathered in the "Online Medical Assessment" allows the UpScriptHealth physician network to work expeditiously with SendRx to process Prior Authorizations

Reimbursement plan is on track

- ❖ Primary axillary hyperhidrosis is a reimbursed medical condition that does not require a separate “code”
- ❖ A patient’s access to *Sofdra*™ will either be:
 - covered with no restrictions;
 - covered with one or two minor obstacles that a Payer (insurance company) may impose;
 - non-formulary (subject to review by the Payer); or
 - not covered
- ❖ In the case of *Sofdra* – the potential obstacles that a Payer (insurance company) may impose are:
 - ensuring that the patient actually *has* the medical condition per the label; and/or
 - the patient confirms they’ve tried an existing product such as Drysol™
- ❖ Qualified commercial patients will have \$0 pharmacy co-pay


Botanix fully engaged with clinical and financial discussions with all target accounts

Zinc Health (GPO) / CVS Caremark PBM	34M	BCBS MA	1.3M	Horizon (BCBS NJ)	650k
Emisar (GPO) / OptumRx PBM	27M	BCBS AL	1.2M	HealthPartners	595k
Ascent Health (GPO) / Express Scripts PBM	22.6M	Florida Blue (BCBS FL)	1.2M	ProCare	560k
Prime Therapeutics*	33.5M	Cambia (Regence)	1.1M	Medical Mutual OH	560k
State Medicaid	80.6M	CareFirst	1.1M	Select Health	560k
VA – Dept of Defense	9.0M	Premera	1.1M	MVP	500k
TRICARE	9.5M	Empire Blue Cross	1M	BCBS SC	422k
United Healthcare	15M	Independence Blue Cross	1M	Emblem Health	400k
Kaiser Permanente	12.2M	DividendGroup (MedImpact)	1M	Centene	380k
CIGNA	9M	Wellmark	950k	HMSA (BCBS Hawaii)	380k
CarelonRx / Anthem	6.1M	BCBS TN	900k	BCBS Arizona	380k
Federal Employee Program	5.5M	Excellus	820k	Tufts Health Plan	307k
HCSC (NM/OK/MT)	465k	BCBS MN	735k	BCBS Kansas City	297k
HCSC BCBS IL	2.8M	BCBS NC	730k	BCBS MS	271k
HCSC BCBS TX	2.6M	Kroger PBM	700k	BCBS KS	260k
Highmark	2.5M	BCBS LA	700k	BCBS NE	236k
Blue Shield California	2.2M	Harvard Pilgrim	125k	BCBS ND	228k
BCBS Michigan	1.7M	Elixir	677k	Health Alliance Plan	206k



WWW.BOTANIXPHARMA.COM

Expected Sofdra™ coverage

Expected Sofdra Coverage
Commercial Lives (167M)



Expected Sofdra Coverage
Including Medicaid/VA/TRICARE (266M)




Sofdra opportunity supported by Japanese licensee experience



Product	Sofpironium topical gel (5%)
Approval Date	September 25, 2020
Launch Date	November 26, 2020
Name	Ecclock®

- ❖ ~350,000 units of Ecclock® have been sold by Botanix’s licensee in Japan in the last 12 months
- ❖ The incidence and prevalence of hyperhidrosis in Japan and the USA is similar
- ❖ The population of Japan is ~1/3rd the size of the USA
- ❖ Kaken has been able to attract significant numbers of new patients – even in the third year of launch

Planned commercialization timeline



WWW.BOTANIXPHARMA.COM

Sofdra™ commercial success is built on 3 pillars

1

LARGE MARKET AND ENGAGED POPULATION

AXILLARY
HYPERHIDROSIS
PATIENTS

~10M


PATIENTS
SEEKING RX
WITH DERM

~3.7M

- ❖ Convert a solid percentage of the 3.7M existing patients seeking treatment
- ❖ Activate a small percentage of the other 6.3M patients who have HH—targeting unsatisfied and ready to treat via digital

2

FRICTIONLESS ACCESS WITH TELEMEDICINE



- ❖ Provide immediate and comfortable access to online diagnosis
- ❖ Rapidly move from diagnosis to prescription utilizing the telemedicine platform

3

PRODUCT SPEED TO PATIENT AND ENSURING EVERY REFILL



- ❖ Avoid distributor fees and other costs by using direct fulfillment
- ❖ Ensure the patient gets every refill to drive positive patient outcomes and profitability